Historical Information

BASKING RIDGE, N.J. (December 2, 2019)  – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, announced today that the

Single administration of CLBS16 durably improves heart function and symptoms with no cell-related adverse events CLBS16 cell therapy shows promise as a significant advancement in treatment of Coronary Microvascular Dysfunction (CMD), a condition that disproportionately afflicts women PHILADELPHIA

Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J. (November 6, 2019)  – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select

BASKING RIDGE, N.J. (October 31, 2019)  – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, announced today that the

BASKING RIDGE, N.J. (October 30, 2019)  – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, announces that the Company

BASKING RIDGE, N.J. (October 1, 2019)  – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, announced today that David

BASKING RIDGE, N.J. (September 5, 2019)  – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, announced today that

LA JOLLA, Calif., Aug. 20, 2019 (GLOBE NEWSWIRE) -- DrugCendR, Inc., a clinical-stage biotech company developing next generation therapies for the treatment of solid tumors, today announced that Dr. Daniel Von Hoff will be a clinical advisor to the company. In this role, Dr.

Confirmatory Phase 3 Study Protocol Finalized for CLBS14 in No-Option Refractory Disabling Angina Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J. (August 8, 2019)  – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics

BASKING RIDGE, NJ, AND MEMPHIS, TENN.  (August 7, 2019)  – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, and